Phosphorusª²32 glass microspheres radioembolization combined with anticancer drugs regional perfusion for lung cancer

    WU Changª²Gui, CHEN Zhangª²Qin, TI Xinª²Yu, DAI Yanª²Li, LI Shuª²Jun, HE Hongª²De

    1Department of Respiratory Medicine, 2Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi¬ðan 710033, China, 3Department of Respiratory Medicine, 2nd People¬ðs Hospital, Shaanxi Province, Xi¬ðan 710003, China

    ¡¾Abstract¡¿ AIM: To evaluate the efficacy and safety of using phosphorusª²32 glass microspheres (32Pª²GMS) as a radioembolizer in patients with lung cancer. METHODS: Twentyª²four patients with intermediate and advanced lung cancer confirmed by histology were enrolled in the study. All of the patients received 2 cycles of systemic chemotherapy: cyclophosphamide+adriamycin+platinum (CAP) regimen for patients with nonsamllª²cell lung cancer (NSCLC) and etoposide+platinum (EP) regimen for patients with smallª²cell cancer (SCLC). At the 8th week, all the patients, who were confirmed to have no obvious morphological changes of tumor by chest CT, were given regional perfusion of anticancer drugs combined with 32Pª²GMS radioembolization. The changes of CT image, clinical symptoms and side effects after therapy were observed. RESULTS: Twentyª²one percent (5/24) of the patients achieved complete remission, 62% (15/24) of patients achieved partial remission, 12% (3/24) of patients had no real changes and 1 patient deteriorated. The treatment was well tolerated, only 1 case showed shortª²term ischemia of the spine cord. CONCLUSION: Sequential therapy with systemic chemotherapy followed by phosphorusª²32 glass microspheres radioembolization combined with regional perfusion of anticancer drugs for advanced lung cancer is feasible and safe. ......